|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500098009 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-28 10:55:53 |
|
注册时间: Date of Registration: |
2025-02-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于脑-肠轴理论研究肠道微生物制剂在儿童抽动障碍中的疗效及作用机制 |
|
Public title: |
To study the effect and mechanism of intestinal microbiotics in children with tic disorder based on brain-gut axis theory |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于脑-肠轴理论研究肠道微生物制剂在儿童抽动障碍中的疗效及作用机制 |
|
Scientific title: |
To study the effect and mechanism of intestinal microbiotics in children with tic disorder based on brain-gut axis theory |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
华英 |
研究负责人: |
邱世彦 |
|
Applicant: |
Hua ying |
Study leader: |
Shiyan Qiu |
|
申请注册联系人电话: Applicant telephone: |
+86 187 5393 2703 |
研究负责人电话:
Study leader's |
+86 135 6392 2356 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
szc20180610@126.com |
研究负责人电子邮件: Study leader's E-mail: |
27106477@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省临沂市兰山区解放路东段27号 |
研究负责人通讯地址: |
山东省临沂市兰山区解放路东段27号 |
|
Applicant address: |
27 East Jiefang Road, Lanshan District, Linyi City, Shandong Province |
Study leader's address: |
27 East Jiefang Road, Lanshan District, Linyi City, Shandong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
临沂市人民医院 |
||
|
Applicant's institution: |
Linyi People's Hospital |
||
|
研究负责人所在单位: |
临沂市人民医院 |
||
|
Affiliation of the Leader: |
Linyi People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
科技伦审第(202311-H-030)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
临沂市人民医院科技伦理委员会 |
||
|
Name of the ethic committee: |
Linyi City People's Hospital science and technology ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-11-14 00:00:00 | ||
|
伦理委员会联系人: |
李明 |
||
|
Contact Name of the ethic committee: |
Li Ming |
||
|
伦理委员会联系地址: |
山东省临沂市兰山区解放路东段27号 |
||
|
Contact Address of the ethic committee: |
27 East Jiefang Road, Lanshan District, Linyi City, Shandong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 539 807 8508 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
临沂市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Linyi People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省临沂市兰山区解放路东段27号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
27 East Jiefang Road, Lanshan District, Linyi City, Shandong Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
项目经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project expenditure |
||||||||||||||||||||||
|
研究疾病: |
抽动障碍 |
||||||||||||||||||||||
|
Target disease: |
Tic disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1、通过与正常对照组比对,分析TS患者的肠道菌群种类,是否存在特殊菌群。 2、分析不同组TS患者添加不同肠道微生物制剂后临床症状改善情况,研究肠道微生物制剂对TS患者治疗的有效性及安全性,制定个性化的治疗方案。 3、通过分析肠道微生物制剂治疗后TS患者肠道菌群及外周血神经递质的变化,探索脑-肠轴与TS的关系,为进一步研究TS的发病机制提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. By comparing with the normal control group, the intestinal flora types of TS patients were analyzed and whether there were special flora. 2. To analyze the improvement of clinical symptoms of TS patients in different groups after adding different intestinal microbial preparations, to study the effectiveness and safety of intestinal microbial preparations in the treatment of TS patients, and to develop personalized treatment plans. 3. By analyzing the changes of intestinal flora and peripheral blood neurotransmitters in TS patients after treatment with intestinal microbiotics, the relationship between brain-gut axis and TS was explored, providing scientific basis for further study of the pathogenesis of TS. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、具有多种运动性抽动及1种或多种发声性抽动,但二者不一定同时出现;2、首发抽动后,抽动的频率可以增多或减少,病程在1年以上;3、发病年龄:5岁-18岁;4、排除某些药物或内科疾病所致。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients with multiple motor tics and one or more vocal tics, but not necessarily both; 2. After the first twitch, the frequency of the twitch can be increased or decreased, and the course of the disease is more than 1 year; 3. The age of onset ranged from 5 to 18 years; 4. Exclude certain drugs or medical diseases. |
||||||||||||||||||||||
|
排除标准: |
1、中度至重度智力残疾;2、在入组前两周食用抗生素和酸奶或益生菌产品者;3、因遗传、感染、中毒及其他原因可能导致抽动或类抽动的临床症状的:比如唐氏综合征、脆性X综合征、结节性硬化症;链球菌感染、脑炎;一氧化碳、汞、蜜蜂中毒等中毒因素;中风、头部创伤等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Moderate to severe intellectual disability; 2. Those who consumed antibiotics and yogurt or probiotic products two weeks before enrollment; 3. Genetic, infection, poisoning and other causes may lead to tic or tic like clinical symptoms: such as Down syndrome, fragile X syndrome, nodular sclerosis; Streptococcal infection, encephalitis; Carbon monoxide, mercury, bee poisoning and other poisoning factors; Stroke, head trauma, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-01 00:00:00 至 To 2025-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究者根据来诊顺序随机分组 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The researchers were randomly assigned according to the order of visits |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
为了保护患者隐私,待试验开始后,需要原始数据共享可联系研究者,通过邮箱共享,邮箱szc20180610@126.com,华英,电话18753932703 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In order to protect the privacy of patients, after the start of the trial, if you need to share the original data, you can contact the investigator by email: szc20180610@126.com, Huaying, telephone: 18753932703 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:通过纸质病例报告表的方式,包括受试者基本信息、临床症状(发作表现及频率)、治疗过程、不良事件,实验所需要采集的指标(耶鲁综合抽动严重程度量表(YGTSS))、智力测试、肠道菌群、血液神经递质、功能磁共振、共患病相关量表等);观察时间为3个月:试验开始前和开始治疗后1个月、3个月。 数据管理:为了保护患者隐私,所有数据均有研究者专人管理,配置专用电脑、设置数据访问权限进行数据收集、存储、处理和分析的流程。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected by paper case report form, including the basic information of the subjects, clinical symptoms (seizure performance and frequency), treatment process, adverse events, indicators needed to be collected in the experiment (Yale Global Tic Severity Scale (YGTSS)), intelligence tests, gut microbiota, blood neurotransmitters, functional magnetic resonance imaging, comorbidities related scales, etc.). The observation period was 3 months: before the start of the trial and 1 and 3 months after the start of treatment. Data management: In order to protect the privacy of patients, all data were managed by researchers. Special computers were configured and data access permissions were set for data collection, storage, processing and analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |